FDA OKs hot-flash drug from Pfizer, Ligand

10/4/2013 | Bloomberg

The FDA has granted Pfizer and Ligand Pharmaceuticals approval for their osteoporosis and hot-flash treatment Duavee. The medication is to be used in postmenopausal women who haven't had a hysterectomy and who suffer moderate to severe hot flashes. The drug is also indicated for prevention of post-menopausal osteoporosis.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC